Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
Complement-driven NETosis mediates immunotherapy resistance in STK11-mutant lung adenocarcinoma.
2026. nov. 3.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC.
2026. nov. 1.· Cancer letters· PUBMED
Vizsgálat
Chinese Multicenter Registry for Peutz-Jeghers Syndrome
2026. okt. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
LKB1 promotes lung adenocarcinoma cell senescence by suppressing the O-GlcNAc glycosylation-mediated activation of telomerase.
2026. szept. 28.· Frontiers in pharmacology· PUBMED
Publikáció
Geraniin alleviates pathological visceral adipose tissue expansion through modulation of β-adrenergic receptor-associated cAMP-LKB1-AMPK signaling in high-fat diet-fed mice.
2026. szept. 24.· Journal of ethnopharmacology· PUBMED
Publikáció
STK11 Adnexal Tumor: Expanding the Spectrum of Female Genital Tumors in Peutz-Jeghers Syndrome.
2026. szept. 24.· Surgical pathology clinics· PUBMED
Publikáció
STK11 deficiency drives NSCLC immune resistance via ETNK2-mediated phosphoethanolamine accumulation.
2026. szept. 16.· International immunology· PUBMED
Publikáció
Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer.
2026. szept. 12.· The Journal of biological chemistry· PUBMED
Publikáció
STK11/LKB1 Loss in Cancer: From Developmental Constraint to Stress-Adapted Malignancy.
2026. szept. 3.· Cancers· PUBMED
Publikáció
STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma.
2026. szept. 1.· Cancer medicine· PUBMED
Preprint
Glutamine stress promotes metastatic potential via hexosamine biosynthetic pathway activity in KRAS/STK11-mutant lung adenocarcinoma.
2026. aug. 27.· Research square· PUBMED
Publikáció
Targeting LKB1-inactivated lung cancers with a stapled peptide inhibitor of the CRTC-CREB pathway.
2026. aug. 21.· Molecular therapy. Oncology· PUBMED
Publikáció
The LKB1-AMPK pathway in NAFLD: molecular mechanisms and therapeutic implications.
2026. aug. 14.· Journal of physiology and biochemistry· PUBMED
Publikáció
GDD, a first-in-class APPL1 activator, restores mitochondrial homeostasis and insulin sensitivity with regulation of LKB1-AMPK axis.
2026. aug. 11.· Phytomedicine : international journal of phytotherapy and phytopharmacology· PUBMED
Publikáció
STK11 c.1062 C > G germline variant in medullary thyroid carcinoma: implications for familial predisposition and genetic counseling.
2026. aug. 3.· Endocrine· PUBMED
Publikáció
LKB1 Dysregulation in Duchenne Muscular Dystrophy Models: Disease Specificity and Epigenetic Control by HDAC Inhibitors.
2026. aug. 1.· Annals of the New York Academy of Sciences· PUBMED
Publikáció
SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.
2026. júl. 20.· Translational oncology· PUBMED
Vizsgálat
LKB1 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer: A Retrospective Cohort Study
2026. júl. 17.· NA · ACTIVE_NOT_RECRUITING· CTGOV
Publikáció
Iron overload suppresses LKB1 and induces IL36G anti-tumor immunity in PDAC metastasis.
2026. júl. 17.· Science advances· PUBMED
Publikáció
Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.
2026. júl. 2.· Cancer immunology research· PUBMED
Publikáció
LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.
2026. júl. 1.· Cancer discovery· PUBMED
Publikáció
Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer.
2026. jún. 30.· Advances in therapy· PUBMED
Publikáció
LKB1 attenuates the transport activity of GLUT1 by regulating the alternative splicing of PKM1/PKM2 in cervical cancer.
2026. jún. 16.· Journal of gynecologic oncology· PUBMED
Publikáció
Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.
2026. jún. 12.· Cancer letters· PUBMED
Publikáció
PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC.
2026. jún. 10.· Biomedical journal· PUBMED
Preprint
SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.
2026. jún. 8.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer.
2026. jún. 2.· Cell reports· PUBMED
Publikáció
Gene Expression Profiling of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 in Cell-Free RNA From Exhaled Breath Condensate: Diagnostic, Prognostic, and Therapeutic Implications in Advanced Lung Adenocarcinoma.
2026. jún. 1.· Cancer reports (Hoboken, N.J.)· PUBMED
Publikáció
LKB1 Loss Sensitizes Lung Tumor Spheres to Mitomet-Induced Ferroptosis, and These Effects are Enhanced by mTOR Inhibition.
2026. máj. 15.· Molecular carcinogenesis· PUBMED
Publikáció
Incidence and Prognostic Value of TP53, STK11, and KEAP1 Mutations Between De Novo Versus Recurrent Actionable Mutation-Negative Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.
2026. máj. 8.· World journal of oncology· PUBMED